| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2009.21.8073 |
| P698 | PubMed publication ID | 20008642 |
| P50 | author | Nicolaus Kröger | Q86950236 |
| Dietger Niederwieser | Q88402151 | ||
| Dietrich W Beelen | Q89402080 | ||
| Tapani Ruutu | Q89849036 | ||
| Jürgen Finke | Q114426803 | ||
| Anja van Biezen | Q114426807 | ||
| Michele Falda | Q114426826 | ||
| P2093 | author name string | Ghulam J Mufti | |
| Andrea Bacigalupo | |||
| Roel Willemze | |||
| Rodrigo Martino | |||
| Ronald Brand | |||
| Marc Boogaerts | |||
| Ziyi Lim | |||
| Jean-Pierre Jouet | |||
| Agnes Devergie | |||
| Emilio Alessandrino | |||
| Theo M De Witte | |||
| P433 | issue | 3 | |
| P921 | main subject | acute myeloid leukemia | Q264118 |
| stem cell transplantation | Q65592366 | ||
| P304 | page(s) | 405-411 | |
| P577 | publication date | 2009-12-14 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia | |
| P478 | volume | 28 |
| Q92017565 | Acute myeloid leukemia cells secrete microRNA-4532-containing exosomes to mediate normal hematopoiesis in hematopoietic stem cells by activating the LDOC1-dependent STAT3 signaling pathway |
| Q48133412 | Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome. |
| Q55515367 | Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia. |
| Q36431041 | Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how? |
| Q26824434 | Allogeneic hematopoietic cell transplantation for myelodysplastic syndromes: lingering uncertainties and emerging possibilities |
| Q36029093 | Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine |
| Q37270993 | Allogeneic hematopoietic cell transplantation in patients ⩾70 years: which patients may benefit? |
| Q39092515 | Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel |
| Q48568744 | Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation |
| Q64949195 | Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings. |
| Q37681792 | Antithymocyte globulin improves the survival of patients with myelodysplastic syndrome undergoing HLA-matched unrelated donor and haplo-identical donor transplants |
| Q37707098 | Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts |
| Q37644959 | Blood concentration of cyclosporine during early post-transplant period may have influence on the occurrence of chronic graft versus host disease in patients who received allogeneic hematopoietic stem cell transplantation |
| Q36608689 | CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse |
| Q38442976 | Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. |
| Q34260505 | Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation |
| Q30675919 | Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data |
| Q44462895 | Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT. |
| Q33830964 | Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. |
| Q91910019 | Comparison of quality of life and depression between hematopoietic stem cell transplantation survivors and their spouse caregivers |
| Q34360641 | Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis |
| Q37899751 | Current status of allogeneic HST for chronic myelomonocytic leukemia |
| Q36063049 | Current status of allogeneic hematopoietic cell transplantation for MDS. |
| Q34013796 | Current therapy of myelodysplastic syndromes |
| Q40282393 | Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning |
| Q48101262 | Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System |
| Q37263146 | Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet |
| Q50584145 | Differences in community and academic practice patterns for newly diagnosed myelodysplastic syndromes (MDS) patients. |
| Q48733699 | Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome |
| Q35202588 | Evidence-based mini-review: Should patients over the age of 60 with INT-2 or high-risk myelodysplastic syndrome undergo allogeneic stem cell transplantation prior to progression to acute myelogenous leukemia? |
| Q36339459 | Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. |
| Q33978945 | Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. |
| Q47639413 | HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia: Results From the Microtransplantation Interest Group |
| Q48226649 | HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM. |
| Q57288448 | Hematopoietic Cell Transplant (HCT) in the Elderly: Myths, Controversies and Unknowns |
| Q38252578 | Hematopoietic Cell Transplantation for Older Patients with MDS. |
| Q86661128 | Hematopoietic stem cell transplantation |
| Q33566684 | Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic |
| Q37169115 | Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). |
| Q64968989 | Impact of intensity of conditioning therapy in patients aged 40-60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation. |
| Q92820179 | Impact of mesenchymal stem cell senescence on inflammaging |
| Q35772737 | In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available? |
| Q46389618 | Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States |
| Q41564676 | Influence of age on outcome after allogeneic hematopoietic cell transplantation: a single center study in patients aged ⩾60. |
| Q36805838 | JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse |
| Q38983160 | Jumping translocations in myelodysplastic syndromes |
| Q36806501 | Last marrow standing: bone marrow transplantation for acquired bone marrow failure conditions. |
| Q64119387 | Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia |
| Q35554703 | Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies |
| Q37739020 | MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes |
| Q38601723 | Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions |
| Q38065878 | Management of adult patients older than 40 years refractory to at least one immunosuppressive course: HLA-identical sibling HSCT using fludarabine-based conditioning |
| Q43451303 | Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia |
| Q34217884 | Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood |
| Q40420210 | Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management |
| Q26829132 | New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome |
| Q34514273 | Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates |
| Q37076932 | Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome |
| Q28084813 | Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia |
| Q47661085 | Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Societ |
| Q36166896 | Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients |
| Q35953348 | Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia |
| Q36090971 | Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. |
| Q38540859 | Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents |
| Q89485899 | Patient eligibility for hematopoietic stem cell transplantation: a review of patient-associated variables |
| Q38287009 | Patient selection for allogeneic hematopoietic cell transplantation (HCT): the evolution of HCT risk assessment |
| Q90209225 | Pre-transplant hypomethylating agents do not influence post-transplant survival in myelodysplastic syndrome |
| Q36544315 | Pre-transplant weight loss predicts inferior outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndrome |
| Q37657429 | Pretransplant comorbidities maintain their impact on allogeneic stem cell transplantation outcome 5 years posttransplant: a retrospective study in a single german institution |
| Q48069751 | Quality of life and outcomes in patients⩾60 years of age after allogeneic hematopoietic cell transplantation |
| Q35565387 | Rare cytogenetic abnormalities in myelodysplastic syndromes |
| Q39282540 | Reduced intensity conditioning of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia in patients older than 50 years of age: a systematic review and meta-analysis |
| Q38366632 | Reduced-intensity conditioned allogeneic SCT in adults with AML. |
| Q36635154 | Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array Testing |
| Q84485392 | Retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning in patients with myelodysplastic syndrome |
| Q36920394 | Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and M |
| Q37419348 | Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia |
| Q84533304 | Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantat |
| Q30353404 | Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. |
| Q34749365 | Significant improvement in survival after unrelated donor hematopoietic cell transplantation in the recent era |
| Q85787857 | Soluble HLA-G molecules and HLA-G 14-base pair polymorphism after allogeneic hematopoietic cell transplantation |
| Q27010653 | Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy |
| Q38248180 | Stopping higher-risk myelodysplastic syndrome in its tracks |
| Q52897534 | The bridge treatment selected at the decision for transplantation did not affect the outcomes in patients with MDS. |
| Q83393625 | The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT |
| Q30316611 | The indications for allogeneic stem cell transplantation in myeloid malignancies |
| Q35317371 | Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms |
| Q35854094 | Transplantation for myelodysplastic syndrome in the era of hypomethylating agents |
| Q30240238 | Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens |
| Q38062302 | Treatment of aplastic anaemia in elderly patients aged >60 years |
| Q38176519 | Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT). |
| Q37863461 | Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike |
| Q35660739 | Who is fit for allogeneic transplantation? |
| Q89257275 | [Advances in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes] |
| Q85509706 | [Combination of busulfan with increased-dose of fludarabine as conditioning regimen for MDS and MDS-AML patients with allo-HSCT] |
Search more.